The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
1. A method of treating or ameliorating levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, said method comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I):
wherein in formula (I):
R 1 , R 2 and R 3 are independently selected from the group consisting of H, cyano, halo, hydroxyl, alkoxy, nitro, C1-6 alkyl, and carboxy;
R 4 and R 5 are independently selected from the group consisting of H, C1-6 alkyl, and substituted C1-6 alkyl; and,
n is 2,
mixtures thereof, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said at least one compound is selected from the group consisting of:
2-amino-4-(2-chlorophenyl)butan-1-ol;
2-(3-aminohexyl)phenol;
4-(2-chlorophenyl)-2-methylamino-butane;
4-(2-fluorophenyl)butan-2-amine;
4-(2-bromophenyl)butan-2-amine;
4-(2-iodophenyl)butan-2-amine;
4-(2-methoxyphenyl)butan-2-amine;
2-(3-aminobutyl)phenol;
3-(3,4-diethoxyphenyl)propan-1-amine;
4-(4-chlorophenyl)butan-2-amine;
4-(4-methoxyphenyl)butan-2-amine;
mixtures thereof, or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein said patient is further administered a drug selected from the group consisting of levodopa, clozapine, bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, and lisuride, a salt thereof and mixtures thereof.
4. The method of claim 1 , wherein said compound is co-administered to said patient with a second pharmaceutical composition comprising levodopa.
5. The method of claim 1 , wherein said compound is administered to said patient a given period of time before a second pharmaceutical composition comprising levodopa is administered to said patient.
6. The method of claim 5 , wherein said given period of time varies from about 2 minutes to about 24 hours.
7. The method of claim 1 , wherein said patient is human.
8. A method of treating or ameliorating Parkinson's Disease in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I):
wherein in formula (I):
R 1 , R 2 and R 3 are independently selected from the group consisting of H, cyano, halo, hydroxyl, alkoxy, nitro, C1-6 alkyl, and carboxy;
R 4 and R 5 are independently selected from the group consisting of H, C1-6 alkyl, and substituted C1-6 alkyl; and,
n is 2,
mixtures thereof, or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein said at least one compound is selected from the group consisting of:
2-amino-4-(2-chlorophenyl)butan-1-ol;
2-(3-aminohexyl)phenol;
4-(2-chlorophenyl)-2-methylamino-butane;
4-(2-fluorophenyl)butan-2-amine;
4-(2-bromophenyl)butan-2-amine;
4-(2-iodophenyl)butan-2-amine;
4-(2-methoxyphenyl)butan-2-amine;
2-(3-aminobutyl)phenol;
3-(3,4-diethoxyphenyl)propan-1-amine;
4-(4-chlorophenyl)butan-2-amine;
4-(4-methoxyphenyl)butan-2-amine;
mixtures thereof, or a pharmaceutically acceptable salt thereof.
10. The method of claim 8 , wherein said compound is administered to said patient as a composition that further comprises at least one drug selected from the group consisting of levodopa, clozapine, bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, and lisuride, a salt thereof and mixtures thereof.
11. The method of claim 8 , wherein said patient is further administered a second pharmaceutical composition comprising at least one drug selected from the group consisting of levodopa, clozapine, bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine, and lisuride, a salt thereof and mixtures thereof.
12. A method of treating or ameliorating levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, said method comprising administering to said patient a therapeutically effective amount of at least one compound selected from the group consisting of:
2-amino-4-(2-chlorophenyl)butan-1-ol;
2-(3-aminohexyl)phenol;
4-(2-chlorophenyl)-2-methylamino-butane;
4-(2-fluorophenyl)butan-2-amine;
4-(2-bromophenyl)butan-2-amine;
4-(2-iodophenyl)butan-2-amine;
4-(2-methoxyphenyl)butan-2-amine;
2-(3-aminobutyl)phenol;
3-(3,4-diethoxyphenyl)propan-1-amine;
4-(4-chlorophenyl)butan-2-amine;
4-(4-methoxyphenyl)butan-2-amine;
mixtures thereof, or a pharmaceutically acceptable salt thereof.
13. A method of treating or ameliorating Parkinson's Disease in a patient, said method comprising administering to said patient a therapeutically effective amount of at least one compound selected from the group consisting of:
2-amino-4-(2-chlorophenyl)butan-1-ol;
2-(3-aminohexyl)phenol;
4-(2-chlorophenyl)-2-methylamino-butane;
4-(2-fluorophenyl)butan-2-amine;
4-(2-bromophenyl)butan-2-amine;
4-(2-iodophenyl)butan-2-amine;
4-(2-methoxyphenyl)butan-2-amine;
2-(3-aminobutyl)phenol;
3-(3,4-diethoxyphenyl)propan-1-amine;
4-(4-chlorophenyl)butan-2-amine;
4-(4-methoxyphenyl)butan-2-amine;
mixtures thereof, or a pharmaceutically acceptable salt thereof.